image
Healthcare - Medical - Devices - NYSE - GB
$ 25.29
0.958 %
$ 11 B
Market Cap
36.13
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one SNN stock under the worst case scenario is HIDDEN Compared to the current market price of 25.3 USD, Smith & Nephew plc is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one SNN stock under the base case scenario is HIDDEN Compared to the current market price of 25.3 USD, Smith & Nephew plc is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one SNN stock under the best case scenario is HIDDEN Compared to the current market price of 25.3 USD, Smith & Nephew plc is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
5.55 B REVENUE
6.40%
425 M OPERATING INCOME
-36.09%
263 M NET INCOME
17.94%
608 M OPERATING CASH FLOW
29.91%
-448 M INVESTING CASH FLOW
5.08%
-200 M FINANCING CASH FLOW
78.40%
2.83 B REVENUE
1.23%
328 M OPERATING INCOME
-26.20%
214 M NET INCOME
137.05%
238 M OPERATING CASH FLOW
-51.45%
-360 M INVESTING CASH FLOW
-37.17%
372 M FINANCING CASH FLOW
430.93%
Balance Sheet Smith & Nephew plc
image
Current Assets 4.03 B
Cash & Short-Term Investments 302 M
Receivables 1.06 B
Other Current Assets 2.67 B
Non-Current Assets 5.96 B
Long-Term Investments 24 M
PP&E 1.47 B
Other Non-Current Assets 4.46 B
Current Liabilities 2.27 B
Accounts Payable 1.02 B
Short-Term Debt 765 M
Other Current Liabilities 490 M
Non-Current Liabilities 2.5 B
Long-Term Debt 2.32 B
Other Non-Current Liabilities 180 M
EFFICIENCY
Earnings Waterfall Smith & Nephew plc
image
Revenue 5.55 B
Cost Of Revenue 1.73 B
Gross Profit 3.82 B
Operating Expenses 3.39 B
Operating Income 425 M
Other Expenses 162 M
Net Income 263 M
RATIOS
70.14% GROSS MARGIN
70.14%
7.66% OPERATING MARGIN
7.66%
4.74% NET MARGIN
4.74%
5.04% ROE
5.04%
2.63% ROA
2.63%
4.76% ROIC
4.76%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Smith & Nephew plc
image
Net Income 263 M
Depreciation & Amortization 527 M
Capital Expenditures -427 M
Stock-Based Compensation 39 M
Change in Working Capital -332 M
Others 111 M
Free Cash Flow 181 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Smith & Nephew plc
image
Wall Street analysts predict an average 1-year price target for SNN of $27 , with forecasts ranging from a low of $27 to a high of $27 .
SNN Lowest Price Target Wall Street Target
27 USD 6.76%
SNN Average Price Target Wall Street Target
27 USD 6.76%
SNN Highest Price Target Wall Street Target
27 USD 6.76%
4. DIVIDEND ANALYSIS
0.93% DIVIDEND YIELD
0.288 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Smith & Nephew plc
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7. News
SNN Stock May Gain on CORIOGRAPH Platform's FDA Clearance for THA Smith & Nephew announces FDA clearance for its CORIOGRAPH platform for total hip arthroplasty. zacks.com - 4 weeks ago
Smith+Nephew introduces CORIOGRAPH™ Pre-Op Planning and Modeling Services for Total Hip Arthroplasty Latest expansion to the CORI◊ Surgical System portfolio provides a personalized solution for patients and surgeons Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces its CORIOGRAPH Pre-Op Planning and Modeling Services is now cleared for total hip arthroplasty (THA) by the United States Food and Drug Administration. Exclusively for users of the CORI Surgical System, this innovative planning software allows for use of either X-rays or CT scans for planning and modeling, enabling surgeons to make a patient-specific plan for the best possible outcome. globenewswire.com - 1 month ago
SNN Stock Might Rise Following FDA Nod for AETOS Stemless Smith & Nephew received FDA 510(k) clearance for a stemless anatomic total shoulder, AETOS Stemless. This represents a significant advancement in shoulder arthroplasty. zacks.com - 1 month ago
Smith+Nephew expands AETOS™ Shoulder System with new stemless option for anatomic shoulder arthroplasty Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has received 510(k) clearance from the United States Food & Drug Administration for a stemless anatomic total shoulder for the AETOS Shoulder System (AETOS Stemless). globenewswire.com - 1 month ago
Smith & Nephew has the potential to pop next year, says leading US investment bank JP Morgan has doubled down on its "overweight" recommendation for Smith & Nephew PLC (LSE:SN) with its analysts deeming the medical device company undervalued, trading near trough levels, with potential for significant re-rating. Despite challenges in the broader European medtech sector, S&N stands out as a value pick with promising recovery prospects. proactiveinvestors.co.uk - 1 month ago
Big investors call for break-up of Smith & Nephew, FT reports Three major investors are pushing medical device maker Smith & Nephew to consider a break-up of the business, the Financial Times reported on Thursday, citing shareholders. reuters.com - 2 months ago
Smith & Nephew: Ready To Reap Demographic, Turnaround Dividends Smith & Nephew's Q3 results led to a 13% share price drop due to reduced FY24 guidance, mainly from lower demand in China. Despite short-term challenges, long-term fundamentals remain strong, presenting a buying opportunity at current lower prices. The company's 12-point plan aims to boost growth and margins, focusing on orthopedics, productivity, and accelerating growth in advanced wound management and sports medicine. seekingalpha.com - 2 months ago
Smith & Nephew plc (SNN) Q3 2024 Earnings Conference Call Transcript Smith & Nephew plc (NYSE:SNN ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 AM ET Company Participants Deepak Nath - CEO & Director John Rogers - CFO & Executive Director Conference Call Participants Jack Reynolds-Clark - RBC Capital Management David Adlington - J.P. Morgan Hassan Al-Wakeel - Barclays Robert Davies - Morgan Stanley Richard Felton - Goldman Sachs Graham Doyle - UBS Lisa Clive - Bernstein Julien Dormois - Jefferies Deepak Nath Good morning, and welcome to the Smith & Nephew third quarter trading update. seekingalpha.com - 2 months ago
Smith+Nephew slashes revenue outlook as China headwinds emerge British medical equipment manufacturer Smith & Nephew PLC (LSE:SN) slashed its full-year revenue outlook to account for a downturn in demand and pricing pressures in the Chinese market. The FTSE 100-listed group now expects full-year revenue growth of 4.5%, compared to 5-6% growth previously expected. proactiveinvestors.co.uk - 2 months ago
Smith & Nephew slashes annual revenue forecast on weak China British medical equipment maker Smith & Nephew cut its annual underlying revenue growth forecast on Thursday to 4.5% from the previous outlook range of 5% to 6%, primarily hurt by challenges in its surgical businesses in China. reuters.com - 2 months ago
RENASYS™ EDGE Negative Pressure Wound Therapy System wins Red Dot Award for Design Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, is proud to announce that its RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System has won the Red Dot Award for Design Concept 2024 in the Medical Devices and Technology Category , recognizing its intuitive pairing of NPWT housed in a patient-friendly design. globenewswire.com - 3 months ago
SNN Stock May Gain Following the Co-Marketing Deal With JointVue Smith & Nephew and JointVue announce a co-marketing agreement for the latter's OrthoSonic 3D Surgery Planning Technology. zacks.com - 3 months ago
8. Profile Summary

Smith & Nephew plc SNN

image
COUNTRY GB
INDUSTRY Medical - Devices
MARKET CAP $ 11 B
Dividend Yield 0.93%
Description Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Contact Building 5, Watford, WD18 8YE https://www.smith-nephew.com
IPO Date Nov. 16, 1999
Employees 18000
Officers Mr. Paul Connolly President of Global Operations Mr. Philip G. Cowdy Chief Corporate Development & Corporate Affairs Officer Ms. Alison Parkes Chief Compliance Officer & Compliance APAC Mr. Joe Metzger Senior Vice President of Marketing Services & Communications Ms. Elga Lohler Chief Human Resources Officer Dr. Vasant Padmanabhan Ph.D. President of Research & Development and Ear, Nose & Throat Ms. Helen Barraclough Group General Counsel & Company Secretary Mr. John Terence Rogers Chief Financial Officer & Executive Director Dr. Deepak S. Nath Ph.D. Chief Executive Officer & Director Mr. Andrew Swift Vice President of Investor Relations